Syremis

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Kynexis

This clinical-stage biotechnology company develops precision therapeutics and small-molecule inhibitors to treat cognitive impairment in patients with schizophrenia and other neurological disorders.

LB Pharmaceuticals

This company develops oral small-molecule antipsychotic therapies for patients with schizophrenia, bipolar depression, and other neuropsychiatric disorders.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Cerevel Therapeutics

This biopharmaceutical company develops neuroscience medicines for patients with mental and neurological conditions including schizophrenia, Parkinson's disease and epilepsy.

Serenatis Bio

This biotechnology company develops small-molecule drugs to treat obsessive-compulsive disorder for patients with mental health conditions.

Biomia

The company develops nature-inspired small molecule therapeutics to treat central nervous system disorders for patients with mental health conditions and chronic pain.